DK1841433T3 - Præparat til behandling af lidelser i centralnervesystemet - Google Patents

Præparat til behandling af lidelser i centralnervesystemet

Info

Publication number
DK1841433T3
DK1841433T3 DK06712847.0T DK06712847T DK1841433T3 DK 1841433 T3 DK1841433 T3 DK 1841433T3 DK 06712847 T DK06712847 T DK 06712847T DK 1841433 T3 DK1841433 T3 DK 1841433T3
Authority
DK
Denmark
Prior art keywords
preparation
treatment
nervous system
central nervous
system disorders
Prior art date
Application number
DK06712847.0T
Other languages
Danish (da)
English (en)
Inventor
Ryuji Ueno
Original Assignee
Sucampo Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sucampo Ag filed Critical Sucampo Ag
Application granted granted Critical
Publication of DK1841433T3 publication Critical patent/DK1841433T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK06712847.0T 2005-01-27 2006-01-26 Præparat til behandling af lidelser i centralnervesystemet DK1841433T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64700805P 2005-01-27 2005-01-27
PCT/JP2006/301704 WO2006080549A2 (en) 2005-01-27 2006-01-26 Method and composition for treating central nervous system disorders

Publications (1)

Publication Number Publication Date
DK1841433T3 true DK1841433T3 (da) 2012-01-16

Family

ID=36740907

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06712847.0T DK1841433T3 (da) 2005-01-27 2006-01-26 Præparat til behandling af lidelser i centralnervesystemet

Country Status (19)

Country Link
US (2) US8202909B2 (enExample)
EP (2) EP1841433B1 (enExample)
JP (1) JP5147404B2 (enExample)
KR (1) KR101354771B1 (enExample)
CN (1) CN101146541B (enExample)
AR (1) AR055846A1 (enExample)
AU (1) AU2006209072B2 (enExample)
BR (1) BRPI0607084A2 (enExample)
CA (1) CA2595898C (enExample)
DK (1) DK1841433T3 (enExample)
ES (1) ES2375082T3 (enExample)
IL (1) IL184578A (enExample)
NO (1) NO340257B1 (enExample)
NZ (1) NZ556710A (enExample)
PL (1) PL1841433T3 (enExample)
PT (1) PT1841433E (enExample)
RU (1) RU2440338C2 (enExample)
TW (1) TWI384988B (enExample)
WO (1) WO2006080549A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI225398B (en) * 1999-07-14 2004-12-21 R Tech Ueno Ltd Composition for treatment of external secretion disorders
WO2008108322A2 (en) * 2007-02-27 2008-09-12 Sucampo Ag Composition and method for protecting mitochondria
JP5390519B2 (ja) * 2007-07-19 2014-01-15 株式会社アールテック・ウエノ １１−デオキシ−プロスタグランジン化合物を含む医薬組成物およびその安定化方法
US8871752B2 (en) 2008-02-19 2014-10-28 Sucampo Ag Method for modulating stem cell growth
US9084815B2 (en) 2009-09-16 2015-07-21 Sucampo Ag Method for treating damage induced by an anti-tumor agent, treating mucositis and treating tumor
JP5755750B2 (ja) * 2010-10-15 2015-07-29 サイノファーム （クンシャン） バイオケミカル テクノロジ カンパニー リミテッド ルビプロストンの調製方法
US9259409B2 (en) 2011-01-24 2016-02-16 Inceptum Research & Therapeutics, Inc. Compositions comprising a prostaglandin for treating neuropsychiatric conditions
RU2013151166A (ru) * 2011-04-19 2015-05-27 Сукампо Аг Способ модуляции активности цитокинов
SG10201606442QA (en) * 2011-08-05 2016-09-29 Sucampo Ag Method for treating schizophrenia
WO2014159679A1 (en) 2013-03-12 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for using lubiprostone to absorb fluid from the subretinal space
AU2015334964B2 (en) * 2014-10-21 2019-06-20 Universitat De Les Illes Balears Method for the synthesis of hydroxy-triglycerides and uses thereof for the prevention and treatment of diseases

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1120243A (en) * 1970-03-09 1968-07-17 Samuelsson Bengt Improvements in or relating to unsaturated carboxylic acid derivatives and the manufacture thereof
BE786215A (fr) * 1971-07-14 1973-01-15 American Cyanamid Co Nouveaux composes apparentes aux prostaglandines naturelles et procedesde leur preparation
ZA764727B (en) * 1975-09-02 1977-07-27 Upjohn Co Prostanoic acid derivatives
SU845774A3 (ru) 1976-04-20 1981-07-07 Фармиталия Карло Эрба С.П.А. (Фирма) Способ получени 13,14-дегидро-11-дЕзОКСипРОСТАглАНдиНОВ
US4131738A (en) * 1977-07-05 1978-12-26 The Upjohn Company 6-Hydroxy-PGE1 compounds
CA1322749C (en) 1987-01-28 1993-10-05 Ryuzo Ueno Prostaglandins of the d series, and tranquilizers and soporifics containing the same
US5166174A (en) 1987-01-28 1992-11-24 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti-ulcers containing same
US5221763A (en) 1987-04-30 1993-06-22 R-Tech Ueno, Ltd. Prostaglandins of the F series
US5317032A (en) 1987-10-02 1994-05-31 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Prostaglandin cathartic
CA2030345C (en) 1989-11-22 1998-12-08 Ryuji Ueno Use of 15-keto-prostaglandin compound for improvement of encephalic function
DK0444844T3 (da) 1990-02-26 1995-04-03 R Tech Ueno Ltd Hidtil ukendte 15-dehydroxy-16-oxoprostaglandiner
CA2039420C (en) 1990-04-04 1996-12-10 Ryuji Ueno Treatment of cataract with 15-keto-prostaglandin compounds
JPH04187637A (ja) 1990-11-21 1992-07-06 Ueno Seiyaku Oyo Kenkyusho:Kk 記憶改善剤
JPH07113012B2 (ja) 1991-01-29 1995-12-06 株式会社アールテック・ウエノ 新規１５−ケト−プロスタグランジン類
JP3183615B2 (ja) * 1994-06-03 2001-07-09 株式会社アールテック・ウエノ 肝・胆道系疾患処置剤
CA2150287C (en) * 1994-06-03 2004-08-10 Ryuji Ueno Agent for treating hepato-biliary diseases
DK0857718T3 (da) 1996-06-10 2002-12-16 Sucampo Ag Endothelinantagonist
ATE401894T1 (de) 1997-11-28 2008-08-15 Sucampo Ag Verwendung von 15-keto-prostaglandin-e verbindungen als endothelin antagonisten
JP3703004B2 (ja) * 1998-07-15 2005-10-05 小野薬品工業株式会社 ５−チア−ω−置換フェニル−プロスタグランジンＥ誘導体
US7176238B1 (en) * 1999-03-01 2007-02-13 Nitromed Inc. Nitrostated and nitrosylated prostaglandins, compositions and methods of use
TWI225398B (en) * 1999-07-14 2004-12-21 R Tech Ueno Ltd Composition for treatment of external secretion disorders
ATE428429T1 (de) * 2000-03-24 2009-05-15 Sucampo Ag Prostaglandine zur behandlung von lichtstrahlung erzeugten augenerkrankungen wie photoretinitis
US6414016B1 (en) 2000-09-05 2002-07-02 Sucampo, A.G. Anti-constipation composition
US20040224995A1 (en) * 2003-05-09 2004-11-11 University Of North Texas Health Science Center At Fort Worth Neuroprotective effects of PPARy agonists against cellular oxidative insults
CN1214794C (zh) * 2003-09-08 2005-08-17 秦正红 前列腺素a1在制备治疗脑缺血性中风疾病的药物中的用途

Also Published As

Publication number Publication date
US8202909B2 (en) 2012-06-19
WO2006080549A2 (en) 2006-08-03
JP2008528440A (ja) 2008-07-31
EP1841433B1 (en) 2011-11-30
AU2006209072A1 (en) 2006-08-03
RU2007132081A (ru) 2009-03-10
BRPI0607084A2 (pt) 2009-08-04
AR055846A1 (es) 2007-09-12
TWI384988B (zh) 2013-02-11
EP1841433A2 (en) 2007-10-10
CN101146541A (zh) 2008-03-19
CN101146541B (zh) 2012-04-11
NZ556710A (en) 2010-08-27
HK1118716A1 (en) 2009-02-20
EP2332545A1 (en) 2011-06-15
IL184578A0 (en) 2007-10-31
PL1841433T3 (pl) 2012-07-31
KR101354771B1 (ko) 2014-01-22
KR20070107065A (ko) 2007-11-06
IL184578A (en) 2015-02-26
CA2595898C (en) 2015-04-28
US20120225938A1 (en) 2012-09-06
US20060194880A1 (en) 2006-08-31
PT1841433E (pt) 2012-02-01
AU2006209072B2 (en) 2011-02-24
NO340257B1 (no) 2017-03-27
WO2006080549A3 (en) 2007-07-05
TW200642690A (en) 2006-12-16
NO20074332L (no) 2007-10-17
CA2595898A1 (en) 2006-08-03
JP5147404B2 (ja) 2013-02-20
ES2375082T3 (es) 2012-02-24
RU2440338C2 (ru) 2012-01-20

Similar Documents

Publication Publication Date Title
DK2019683T4 (da) Indgivelse af vækstfaktorer til behandling af CNS-lidelser
DK1730119T3 (da) Imidazolforbindelser til behandling af neurodegenerative forstyrrelser
DK1812110T3 (da) Apparat til behandling af dermatologiske lidelser
DK1828164T3 (da) Fremgangsmåde til fremstilling af N-phenylpyrazol-1-carboxamider
DK1778668T3 (da) Fremgangsmåde til fremstilling af dihydropteridion
DK2545939T3 (da) Tetrahydrobiopterin til behandling af tilstande associeret med forhøjede phenylalaninniveauer
IL187168A0 (en) Improved nanobodiestm for the treatment of aggregation-mediated disorders
DK2102169T3 (da) Indazolylamidderivater til behandling af glucocorticoidreceptormedierede forstyrrelser
DK1869025T3 (da) Piperazin-substituerede benzothiophener til behandling af mentale lidelser
DK1893586T3 (da) Fremgangsmåde til fremstilling af 1-alkyl-3-phenyluraciler
DK2504005T3 (da) Anvendelse af 1,3-diphenylprop-2-en-1-on-derivater til behandling af lever-sygdomme
DK1720571T3 (da) Fremgangsmåde til behandling af hæmolytisk sygdom
DK1928438T3 (da) Anvendelse af ibudilast til behandling af stofafhængighed
DK1833799T3 (da) 3-phenyl-pyrazol derivater, som modulatorer af 5-HT-2a-serotonin receptor nyttig til behandlingen af sygdomme relateret hertil
IL178648A0 (en) Substituted morpholine compounds for the treatment of central nervous system disorders
DK2418201T3 (da) Polymorfe former af (2S)-(4E)-N-methyl-5-[3-(5-isopropoxypyridin) yl]-4-penten-2-amin p-hydroxybenzoat til behandling af centralnervesystemlidelser
DK1868600T3 (da) Spirocyklisk cyclohexanderivat til behandling af stofafhængighed
ZA200901523B (en) Use of extracts for the treatment of viral disorders
DK1890684T3 (da) Behandling af søvn/vågenhedsforstyrrelser
DK1937633T3 (da) Biphenyloxyeddikesyrederivater til behandling af respiratoriske sygdomme
BRPI0820440A2 (pt) Inibidores aldh-2 no tratamento de desordens psiquiátricas
DK1765355T3 (da) Benzoxazin til behandling af luftvejslidelser
DK2117565T3 (da) Anvendelse af chitosaner til behandlingen af negleinflammatoriske sygdomme
DK1841433T3 (da) Præparat til behandling af lidelser i centralnervesystemet
DK1919909T3 (da) Syntesemetoder og mellemprodukter for stereoisomere forbindelser, der er anvendelige til behandling af gastrointestinale forstyrrelser og forstyrrelser i centralnervesystemet